Leerink Partners Reiterates Outperform Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “outperform” rating restated by stock analysts at Leerink Partners in a research note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $5.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 237.84% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on IMUX. Piper Sandler reissued an “overweight” rating and issued a $28.00 price target on shares of Immunic in a research note on Tuesday, July 16th. B. Riley started coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price on the stock. Finally, StockNews.com raised shares of Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $11.20.

Immunic Price Performance

Shares of IMUX stock opened at $1.48 on Monday. The firm’s 50-day moving average is $1.38 and its two-hundred day moving average is $1.31. Immunic has a 12 month low of $0.95 and a 12 month high of $1.92. The company has a market capitalization of $133.32 million, a PE ratio of -0.81 and a beta of 1.82.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. During the same quarter in the previous year, the company earned ($0.54) earnings per share. Sell-side analysts forecast that Immunic will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in Immunic during the 1st quarter worth $25,000. Sierra Summit Advisors LLC acquired a new stake in Immunic during the 4th quarter worth $487,000. Ikarian Capital LLC raised its position in Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares during the last quarter. Vanguard Group Inc. raised its position in Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new position in shares of Immunic in the 1st quarter valued at about $9,266,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.